Skip to main content
Contact us

Leading CDMO Companies in the UK

Your Trusted Partners in the UK for Contract Manufacturing and Development.

Applied Filters:Europe×Clear All
Showing 12 facilities
Pharmaron API Commercial Synthesis Cramlington (UK)
United Kingdom

Pharmaron API Commercial Synthesis Cramlington (UK)

Pharmaron

Commercial API Small Molecules Synthesis.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CARBOGEN AMCIS | Manchester, UK
United Kingdom

CARBOGEN AMCIS | Manchester, UK

CARBOGEN AMCIS

Discover our cosmetic ingredient manufacturing capabilities, fine chemicals and custom synthesis of pharma intermediates capabilities.

REGION: Europe

COMPLIANCE: ISO, Halal Research Council, ECOVADIS

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING

SERVICES: Development services, Manufacturing services, Analytical / QC services

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Seda Pharma Development Services
United Kingdom

Seda Pharma Development Services

Seda Pharma Development Services Ltd

Seda Pharmaceutical Development Services specialises in integrated Pharmaceutical Development and Clinical Pharmacology.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (D) Dermatologicals, (M) Musculoskeletal system, (N) Nervous system, (B) Blood and blood forming organs

MARKETS: TGA (Australia), Rest of World, EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India)

BATCH SIZE: Small, Medium

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day)

COMPLIANCE: MHRA (UK GMP), ECOVADIS

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

REGION: Europe

USE: Human

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

Limited view

CHEMICAL-SYNTHETIC manufacturing site

MAI network supplier

R&D and GMP manufacturing site, Bowburn, Durham, UK

Location available after registration

Limited view

CHEMICAL-SYNTHETIC manufacturing site

MAI network supplier

R&D Centre

Location available after registration

Limited view

CDMO/CMO facility

MAI network supplier

Global CDMO partner providing small molecule, biologics and analytical services, supporting drug development, manufacture and supply from concept to patient

Location available after registration

Suggested Results

These facilities match your main criteria but not every optional filter — including other countries in the same region.

HISTOCELL S.L. | Cell Therapy, Exosomes & Secretomes
Spain

HISTOCELL S.L. | Cell Therapy, Exosomes & Secretomes

HISTOCELL

Histocell is a Spanish CDMO that develops and manufactures cell therapies, secretomes and exosomes, as well medical devices.

SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), CDSCO (India), TGA (Australia)

COMPLIANCE: ISO, EMA (EU GMP)

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: COSMETICS, FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

USE: Human, Veterinary

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism

BATCH SIZE: Small, Medium

REGION: Europe

CARBOGEN AMCIS | Vionnaz
Switzerland

CARBOGEN AMCIS | Vionnaz

CARBOGEN AMCIS

Highly Potent APIs development and small-scale cGMP production including chromatography and lyophilization.

SERVICES: Development services, Analytical / QC services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

USE: Human, Veterinary

BATCH SIZE: Small

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

REGION: Europe

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

FAES FARMA | DERIO facility
Spain

FAES FARMA | DERIO facility

FAES FARMA

Developer and manufacturer of human medicinal products.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human

BATCH SIZE: Large, Small, Medium

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Europe

Laboratorios Grifols | Murcia Plant
Spain

Laboratorios Grifols | Murcia Plant

Grifols International

Sterile manufacturing solutions (small molecules) in flexible bags.

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), ANMAT (Argentina), MFDS (South Korea), TGA (Australia)

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

SERVICES: Logistics, Analytical / QC services, Packaging, Quality Assurance services, Manufacturing services

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (C) Cardiovascular system, (A) Digestive tract and metabolism

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

REGION: Europe

Cenexi
France

Cenexi

Cenexi

GMP plant on a four-hectare site is located 9 km east of Paris. It is a center of excellence for injectable ampoules.

SERVICES: Development services, Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), EDE (UAE), TGA (Australia)

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), NMPA (China GMP), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

USE: Human, Veterinary

BATCH SIZE: Large, Small, Medium

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & no medical use, High potential for abuse & medical use, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (N) Nervous system, (J) Antiinfectives for systemic use, (D) Dermatologicals, (P) Antiparasitic products, insecticides and repellents, (M) Musculoskeletal system, (L) Antineoplastic and immunomodulating agents, (C) Cardiovascular system, (A) Digestive tract and metabolism

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

REGION: Europe

Nexora Cell and Tissue Therapy Manufacturing Site
Germany

Nexora Cell and Tissue Therapy Manufacturing Site

Green Phoenix Labs GmbH

Licensed ATMP site in Germany. GMP manufacturing and QP batch release for cell and tissue therapies.

SERVICES: Development services, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

MARKETS: EMA (EU)

BSL (Biological Safety Level): 1, 2

USE: Human

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, Low potential for abuse

THERAPEUTIC AREAS OF EXPERTISE (ATC): (S) Sensory organs, (N) Nervous system, (D) Dermatologicals, (B) Blood and blood forming organs, (R) Respiratory system, (M) Musculoskeletal system, (G) Genito urinary system and sex hormones, (C) Cardiovascular system, (A) Digestive tract and metabolism

BATCH SIZE: Small, Medium

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

COMPLIANCE: EMA (EU GMP)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES, BIOLOGICS

REGION: Europe

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+6 more facilities

Create free account

The United Kingdom has become a leading hub for Contract Development and Manufacturing Organizations (CDMOs) in the pharmaceutical sector. CDMOs in the UK and pharmaceutical CDMO UK services provide end-to-end solutions from drug development to large-scale commercial manufacturing, helping biotech companies and pharmaceutical firms across Europe and globally bring innovative therapies to market efficiently and cost-effectively.

Why Choose CDMO Companies in the UK?

UK CDMO providers and pharmaceutical manufacturing UK facilities are renowned for their high-quality infrastructure, regulatory compliance, and experienced workforce. Leading CDMO UK companies specialize in a wide range of dosage forms, including oral solids, injectables, biologics, and complex formulations such as lyophilized products and sustained-release systems. Most British CDMO facilities maintain certifications from global regulatory authorities including FDA, EMA, MHRA, and WHO, ensuring full compliance throughout preclinical, clinical, and commercial manufacturing stages.

The UK’s strategic location, robust life sciences ecosystem, and efficient pharmaceutical supply chain UK networks provide excellent access to European and global markets. With strong government support for pharmaceutical R&D and innovation, UK CDMOs are well-positioned to handle complex drug development projects.

Key Services Offered by CDMOs in the UK

Accelerating formulation stability through Drug Development Services UK: Complete formulation development, analytical method development and validation, process optimization, and scale-up services to ensure robust, scalable pharmaceutical products.

Scaling up production via Pharmaceutical Manufacturing UK: High-volume production across multiple formats including tablets, capsules, injectables, semi-solids, and biologics, providing flexible, high-quality manufacturing solutions.

Synthesizing active compounds with API Manufacturing UK: Extensive expertise in Active Pharmaceutical Ingredient synthesis, process development, and commercial-scale API manufacturing with rigorous quality control.

Navigating global regulatory approvals via Regulatory Support UK: Assistance with regulatory filings, MHRA submissions, EMA compliance, and guidance for FDA or other international regulatory approvals.

Securing global product integrity using Pharmaceutical Packaging UK: Full primary and secondary packaging solutions including blister packs, vial filling, and customized packaging that meet global regulatory standards.

Advantages of Partnering with UK CDMO Companies

Ensuring compliance standards with High-Quality Manufacturing UK: UK CDMO providers deliver premium manufacturing services with strict adherence to international quality standards.

Utilizing high-containment suites in Advanced Facilities UK: Modern pharmaceutical facilities UK feature state-of-the-art equipment, aseptic processing, and high-containment capabilities for complex molecules and biologics.

Streamlining global filings through Regulatory Expertise UK: Extensive experience with MHRA, EMA, FDA, and other global regulatory requirements ensures smooth market access.

Leveraging specialized chemistry via Technical Expertise UK: Highly skilled workforce with strong capabilities in complex chemistry, biologics, and innovative drug delivery systems.

Optimizing raw material logistics through Supply Chain Advantages: Well-established pharmaceutical supply chain UK networks ensure reliable sourcing of raw materials, intermediates, and efficient global distribution.

Driving biopharmaceutical R&D with Innovation Capabilities: Strong focus on pharmaceutical innovation UK with significant R&D investment in novel formulations, biologics, and advanced manufacturing technologies.

Leading CDMO Companies in the UK

Top-rated CDMO companies in the UK and pharmaceutical manufacturers in the UK include:

Pharmaron: CDMO services UK provider specializing in commercial API Small Molecules Synthesis. [See CDMO profile]

Cambrex: Cambrex Edinburgh delivers world-class solid form screening, including salt, polymorph, co-crystal, and crystallization screening, along with other specialized screening services. [See CDMO profile]

Seda Pharma Development Services: Specialised in integrated pharmaceutical development and clinical pharmacology to support the efficient development of optimal medicinal products, from conventional to complex formulations, leveraging strong scientific expertise. [See CDMO profile]

CARBOGEN AMCIS | Manchester, UK: Development of highly potent APIs and small-scale cGMP manufacturing, including chromatography and lyophilization capabilities. [See CDMO profile]

Related CDMO Information

Leading CDMO Companies in Europe

Leading CDMO Companies in Ireland

Find the Right CDMO Partner in the UK

Selecting the ideal CDMO UK partner requires careful assessment of technical capabilities, quality systems, regulatory compliance, and cultural fit. Our network connects you with pre-vetted CDMO companies UK that align with your project needs and strategic objectives.

Whether you need early-stage development support, clinical trial material manufacturing, or commercial-scale production, we provide expert guidance to navigate the pharmaceutical manufacturing UK landscape and establish successful partnerships with leading UK CDMOs.

Contact our UK CDMO specialists today to identify the perfect manufacturing partner and optimize your pharmaceutical development strategy in the UK’s dynamic life sciences sector.